RT Journal Article
SR Electronic
T1 Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP bjophthalmol-2021-319417
DO 10.1136/bjophthalmol-2021-319417
A1 Jeremy Allan Goldfarb
A1 Renata Ferrarotto
A1 Neil Gross
A1 Ryan Goepfert
A1 James Matthew Debnam
A1 Brandon Gunn
A1 Priyadharsini Nagarajan
A1 Bita Esmaeli
YR 2021
UL http://bjo.bmj.com/content/early/2021/10/08/bjophthalmol-2021-319417.abstract
AB Purpose To report on the outcomes of immunotherapy in patients with locally advanced periorbital squamous cell carcinoma.Methods We performed a retrospective chart review of seven consecutive patients with locally advanced periorbital cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy. Treatments and therapeutic outcomes were reviewed.Results Of the seven patients, six were treated with cemiplimab, and one was treated with pembrolizumab. Five patients were treated with immunotherapy as neoadjuvant therapy before planned surgical resection; two patients received immunotherapy for treatment of advanced recurrent lesions deemed unresectable following multiple previous excisions and radiation therapy. In all seven patients, measurable clinical and/or radiologic response was observed.Conclusions Our findings support the emerging role of anti-PD-1 immunotherapy in the management of locally advanced periorbital cutaneous squamous cell carcinoma.All data relevant to the study are included in the article or uploaded as supplemental information. Additional data, if required, is available by contacting the corresponding author.